Roche’s Columvi Approval By US FDA Takes Bispecific Antibodies Into Fixed-Duration Therapy

 
• By Bridget Silverman
  
bridge
Columvi takes bispecific antibody treatment to new places. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers